This edition of Impacts includes the following articles:
Do discovery organizations need to formalize project and portfolio management?
Few pharmaceutical companies have enough new drug candidates of sufficiently high quality coming out of their discovery labs. And they don’t necessarily manage the candidates that they do have in the best possible manner, either. This article focuses on how the organization of discovery in pharmaceutical and biotechnology companies can improve their performance through better blocking and tackling – what we call Project and Portfolio Management.
No Single Market with a Single European Price
Europe is a difficult environment for pharmaceutical companies. Price controls are imposed by most EU member states in order to control expenditure on government reimbursement of pharma purchases. This negatively impacts pharma companies' competitiveness and profitability, because governments' cost containment measures, such as pricing and reimbursement procedures, limit the freedom to market a product and can also delay a product's launch.
A spoonful of sugar… but is the medicine going down?
Mary Poppins may have found an answer, but in the real world we’re wasting up to $60 billion each year because patients fail to take prescribed drugs properly. The pharmaceutical industry is subject to many increasing pressures - few new blockbusters products, costs and potential litigation - so why does the industry add to its challenges by doing so little to help improve patient compliance? What could it do to conserve costs ? The answer lies in the packaging of the product.
Aegate commences the first ‘Authentication at the point of Dispensing'™ pilot
Aegate is PA Consulting Group’s latest venture, set up to test a new solution to combat pharmaceutical fraud. Recent market developments, new EU member states and changing legislation in the US have put the spotlight on the need for pharmaceutical companies to provide a checking mechanism for the authenticity of their products. Aegate’s solution, ' Authentication at the point of dispensing™’, is currently being piloted in the UK. Results are expected to be available in early 2005.
